ArticleMolecular biology reports2026
Palmitate and oleate differentially regulate oxidative stress and drug resistance markers in steatotic HepG2 cells.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundExcess palmitate (PA) induces lipid accumulation, and oxidative stress in hepatocytes, contributing to metastasis and multidrug resistance in hepatocellular carcinoma (HCC). Oleate (OA) attenuates PA-induced lipotoxicity. This study examines how PA, OA, and their combination modulate oxidative stress, NRF2 signaling, and regulators of metastasis (MMP9) and multidrug resistance (MRP1) in HepG2 cells.
methodsHepG2 cells were treated for 24 h with IC₅₀ concentrations of PA (0.8 μM), OA (1.0 μM), or PA/OA (0.6:0.9 μM), determined by MTT assay. Lipid droplets were quantified by Oil Red O staining. Reactive oxygen species (ROS) and malondialdehyde (MDA) levels were measured spectrophotometrically. Gene expression of NRF2, MRP1, and MMP9 was assessed by RT-qPCR.
resultsPA and OA induced comparable lipid droplet accumulation (P > 0.05), whereas PA/OA synergistically enhanced steatosis (P < 0.0001 vs. control). PA significantly increased ROS (P < 0.01) and showed a tendency to elevate MDA (P = 0.07), while PA/OA normalized ROS to control levels (P > 0.05 vs. control) and reduced MDA (P < 0.05). PA/OA robustly upregulated NRF2 (~ 5.2-fold; P < 0.01) and MRP1 (~ 5.3-fold; P < 0.0001), with significant differences vs. PA and OA alone. MMP9 expression remained unchanged across all treatments (P > 0.05).
conclusionCo-administration of OA counteracts PA-induced oxidative stress and lipotoxicity despite enhancing steatosis, mediated by pronounced NRF2 pathway activation and MRP1 upregulation. This adaptive cytoprotective response may promote tumor cell survival and multidrug resistance in HCC, highlighting the context-dependent role of dietary fatty acid composition in hepatocarcinogenesis and therapeutic vulnerability.
Indexed as
Identifiers
42043485What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.